371 related articles for article (PubMed ID: 23991729)
1. Lung cancer biomarkers: present status and future developments.
Cagle PT; Allen TC; Olsen RJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
[TBL] [Abstract][Full Text] [Related]
2. The classification of lung carcinoma: time to change the morphology-based approach?
Pelosi G; Sonzogni A; Viale G
Int J Surg Pathol; 2010 Jun; 18(3):161-72. PubMed ID: 20460313
[TBL] [Abstract][Full Text] [Related]
3. Molecular prognostication of non-small cell lung cancer.
Tsao MS; Jablons DM
Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
[No Abstract] [Full Text] [Related]
4. Lung cancer genotype-based therapy and predictive biomarkers: present and future.
Cagle PT; Allen TC
Arch Pathol Lab Med; 2012 Dec; 136(12):1482-91. PubMed ID: 23194040
[TBL] [Abstract][Full Text] [Related]
5. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
7. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
8. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer.
Kulesza P; Ramchandran K; Patel JD
Am J Clin Pathol; 2011 Aug; 136(2):228-38. PubMed ID: 21757595
[TBL] [Abstract][Full Text] [Related]
9. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
Tomaszek SC; Huebner M; Wigle DA
Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
[TBL] [Abstract][Full Text] [Related]
10. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
Cagle PT; Sholl LM; Lindeman NI; Alsabeh R; Divaris DX; Foulis P; Lee G; Neal JW; Nowak JA; Yu PP;
Arch Pathol Lab Med; 2014 Feb; 138(2):171-4. PubMed ID: 23808401
[No Abstract] [Full Text] [Related]
11. Molecular pathology of non-small cell lung cancer: a practical guide.
Aisner DL; Marshall CB
Am J Clin Pathol; 2012 Sep; 138(3):332-46. PubMed ID: 22912349
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
Dacic S
Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
[TBL] [Abstract][Full Text] [Related]
13. The role of targeted therapy in non-small cell lung cancer.
Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
[TBL] [Abstract][Full Text] [Related]
14. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer.
Jakobsen JN; Sørensen JB
Cancer Chemother Pharmacol; 2012 Feb; 69(2):289-99. PubMed ID: 22130585
[TBL] [Abstract][Full Text] [Related]
15. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
16. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
17. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
Kris MG
Oncologist; 2005 Oct; 10 Suppl 2():23-9. PubMed ID: 16272456
[TBL] [Abstract][Full Text] [Related]
18. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.
Masuda K; Takano A; Oshita H; Akiyama H; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
Clin Cancer Res; 2011 Dec; 17(24):7712-22. PubMed ID: 22016508
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine for lung cancer: new challenges for pathology.
Kerr KM
Histopathology; 2012 Mar; 60(4):531-46. PubMed ID: 21916947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
